Two years after Boston-based HotSpot Therapeutics launched, the company has secured $65 million in Series B funding to advance the development of its allosteric therapies that target “regulatory hotspots” in the body into the clinic.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,